---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-034828"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:49:31.013178+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "medium"
source: SEC EDGAR
---

# Anixa Biosciences reaches maximum tolerated dose in Phase 1a trial of breast cancer vaccine

## Summary
- Maximum tolerated dose achieved in Phase 1a trial of preventative breast cancer vaccine.
- Vaccine developed in collaboration with Cleveland Clinic.
- Results presented at San Antonio Breast Cancer Symposium; press release and poster furnished.

## SEC filing metadata
- accession: 0001493152-22-034828
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315222034828/0001493152-22-034828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315222034828/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-034828
- JSON: https://secwatch.observer/filing/0001493152-22-034828.json
- Plain text: https://secwatch.observer/filing/0001493152-22-034828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.